CL2014000134A1 - Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. - Google Patents
Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.Info
- Publication number
- CL2014000134A1 CL2014000134A1 CL2014000134A CL2014000134A CL2014000134A1 CL 2014000134 A1 CL2014000134 A1 CL 2014000134A1 CL 2014000134 A CL2014000134 A CL 2014000134A CL 2014000134 A CL2014000134 A CL 2014000134A CL 2014000134 A1 CL2014000134 A1 CL 2014000134A1
- Authority
- CL
- Chile
- Prior art keywords
- protein
- psoriasis
- tnf
- arthritis
- diseases
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 206010003246 arthritis Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000134A1 true CL2014000134A1 (es) | 2014-07-25 |
Family
ID=44586854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000134A CL2014000134A1 (es) | 2011-07-19 | 2014-01-17 | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130243764A1 (es) |
| EP (2) | EP3009450A1 (es) |
| JP (1) | JP2014524748A (es) |
| KR (1) | KR20140054085A (es) |
| CN (1) | CN103748110A (es) |
| AU (1) | AU2012285786B2 (es) |
| BR (1) | BR112014000341A2 (es) |
| CA (1) | CA2841105A1 (es) |
| CL (1) | CL2014000134A1 (es) |
| CO (1) | CO6862106A2 (es) |
| CR (1) | CR20140029A (es) |
| DO (1) | DOP2014000007A (es) |
| EA (1) | EA201391789A1 (es) |
| ES (1) | ES2600854T3 (es) |
| GB (1) | GB201112429D0 (es) |
| MA (1) | MA35345B1 (es) |
| MX (1) | MX2014000739A (es) |
| PE (1) | PE20141660A1 (es) |
| SG (1) | SG10201601154QA (es) |
| WO (1) | WO2013011076A2 (es) |
| ZA (1) | ZA201400062B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| CA2866692A1 (en) | 2012-03-07 | 2013-07-11 | Cadila Healthcare Limited | Formulations which prevent formation of antibody aggregates |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201504249XA (en) | 2012-09-02 | 2015-07-30 | Abbvie Inc | Methods to control protein heterogeneity |
| PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| EP3514175A1 (fr) * | 2012-12-17 | 2019-07-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| CA2898262A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| SG11201504260UA (en) * | 2013-03-14 | 2015-10-29 | Abbvie Inc | Low acidic species compositions and methods for producing and using the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2015007912A1 (en) * | 2013-07-19 | 2015-01-22 | Hexal Ag | Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| MX2016004926A (es) * | 2013-10-16 | 2017-01-18 | Oncobiologics Inc | Formulaciones de tampon para la estabilidad de anticuerpo mejorada. |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| PT2946765T (pt) * | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| WO2016036918A1 (en) * | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| WO2016120413A1 (en) * | 2015-01-28 | 2016-08-04 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| EP3395835B1 (en) * | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| AU2017213775A1 (en) | 2016-02-03 | 2018-08-16 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| KR20180127320A (ko) | 2016-03-14 | 2018-11-28 | 유니버시티에트 이 오슬로 | 변경된 FcRn 결합을 갖는 조작된 면역글로불린 |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| SG11201900616UA (en) | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| TW202300515A (zh) * | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| ES2933808T3 (es) * | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
| JP6974500B2 (ja) * | 2017-01-13 | 2021-12-01 | ハンクス バイオファーマシューティクス，インコーポレイテッド | ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法 |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR20200035972A (ko) * | 2017-08-11 | 2020-04-06 | 리서치 디벨럽먼트 파운데이션 | 증강된 혈청 반감기를 위한 조작된 항체 fc 변이체 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| KR20200115568A (ko) * | 2018-01-26 | 2020-10-07 | 젠자임 코포레이션 | FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체 |
| WO2023098694A1 (zh) * | 2021-11-30 | 2023-06-08 | 江苏恒瑞医药股份有限公司 | 一种抗sost抗体药物组合物及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| HU221984B1 (hu) * | 1996-02-09 | 2003-03-28 | Basf Ag | Humán TNFalfa-t kötő antitestek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| ES2727425T3 (es) * | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| EP2089428B1 (en) * | 2006-10-27 | 2013-11-20 | AbbVie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| CA2695484C (en) | 2007-08-20 | 2018-05-01 | Glaxo Group Limited | Production method of therapeutic proteins based on codon adaptation |
| WO2009073569A2 (en) * | 2007-11-30 | 2009-06-11 | Abbott Laboratories | Protein formulations and methods of making same |
| EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| SI2808343T1 (sl) * | 2007-12-26 | 2019-10-30 | Xencor Inc | Fc-variante s spremenjeno vezavo na FcRn |
| WO2009083246A1 (en) * | 2007-12-31 | 2009-07-09 | Bayer Schering Pharma Aktiengesellschaft | Antibodies to tnf alpha |
| FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
| CN104740631B (zh) * | 2008-10-29 | 2019-04-16 | 阿布林克斯公司 | 单域抗原结合性分子的制剂 |
| EP2401298A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| JP5836807B2 (ja) * | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | Ｉｌ−１７結合タンパク質 |
| JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤 |
| US20120076787A1 (en) * | 2009-05-28 | 2012-03-29 | Peter Adamson | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye |
| WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| EP2637690B1 (en) | 2010-11-11 | 2016-09-21 | AbbVie Biotechnology Ltd | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 CA CA2841105A patent/CA2841105A1/en not_active Abandoned
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Application Discontinuation
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/en active Application Filing
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/en not_active Withdrawn
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/en active Active
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012285786B2 (en) | 2016-05-12 |
| ZA201400062B (en) | 2017-08-30 |
| CO6862106A2 (es) | 2014-02-10 |
| JP2014524748A (ja) | 2014-09-25 |
| ES2600854T3 (es) | 2017-02-13 |
| CN103748110A (zh) | 2014-04-23 |
| SG10201601154QA (en) | 2016-03-30 |
| EA201391789A1 (ru) | 2014-06-30 |
| BR112014000341A2 (pt) | 2017-02-14 |
| MA35345B1 (fr) | 2014-08-01 |
| WO2013011076A3 (en) | 2013-04-04 |
| AU2012285786A1 (en) | 2014-02-06 |
| EP2734548B1 (en) | 2016-08-17 |
| NZ618897A (en) | 2016-02-26 |
| MX2014000739A (es) | 2014-02-19 |
| GB201112429D0 (en) | 2011-08-31 |
| US20130243764A1 (en) | 2013-09-19 |
| WO2013011076A2 (en) | 2013-01-24 |
| CA2841105A1 (en) | 2013-01-24 |
| DOP2014000007A (es) | 2014-04-30 |
| PE20141660A1 (es) | 2014-11-21 |
| CR20140029A (es) | 2014-03-05 |
| KR20140054085A (ko) | 2014-05-08 |
| EP3009450A1 (en) | 2016-04-20 |
| EP2734548A2 (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000134A1 (es) | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. | |
| CL2013001625A1 (es) | Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa. | |
| CL2014001054A1 (es) | Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra. | |
| TN2014000438A1 (en) | Anti-fcrn antibodies | |
| BR112012009854A8 (pt) | proteínas de ligação de antígeno il-23 humana | |
| CL2012002783A1 (es) | Proteinas de unión humanizada que se une al factor de necrosis tumoral alfa humano (tnf-alfa); composicion para liberar una proteina que se une a tnf-alfa; construccionde una proteina que puede unirse al tnf-alfa; acido nucleico, vector y celula huesped que comprenden dicha construccion. | |
| CL2014000699A1 (es) | Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco. | |
| CL2013001975A1 (es) | Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta. | |
| CL2014003568A1 (es) | Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante. | |
| EP3034514A4 (en) | Antibody specifically binding to glp-1r and fusion protein thereof with glp-1 | |
| CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CO7250445A2 (es) | Proteínas de unión a antígeno st2 | |
| CL2015000757A1 (es) | Una proteina | |
| CL2011002831A1 (es) | Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo. | |
| CL2013003043A1 (es) | Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune. | |
| CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2014001217A1 (es) | Polinucleotido que codifica un polipeptido de neurotoxina que muestra una menor duracion del efecto biologico en un sujeto; vector; celula huesped; polipeptido codificado; metodo de fabricacion del polipeptido; anticuerpo que se une al polipeptido; y su uso. | |
| CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
| CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
| EA201690503A1 (ru) | Антитела | |
| CL2013001944A1 (es) | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn | |
| PH12016500753B1 (en) | Antibodies specific to fcrn | |
| MX2015012420A (es) | Nuevas proteinas de union para pcsk9. | |
| CL2015001229A1 (es) | Método de selección de proteínas ligantes de antígeno her3 humano y que no reaccionan cruzadamente con her4; proteína ligante; anticuerpo ligante de her3; ácido nucleico que lo codifica; célula huésped; método de producción; formulación farmacéutica que lo comprende; uso para tratar el cáncer; y epítopos. |